These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 18694365)

  • 1. Myocardial infarction, heart failure and sympathetic nervous system activity: new pharmacological approaches that affect neurohumoral activation.
    Ciarka A; van de Borne P; Pathak A
    Expert Opin Investig Drugs; 2008 Sep; 17(9):1315-30. PubMed ID: 18694365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The treatment of heart failure: the role of neurohumoral activation.
    Middlekauff HR; Mark AL
    Intern Med; 1998 Feb; 37(2):112-22. PubMed ID: 9550589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
    Adams KF
    Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S4-13. PubMed ID: 15160833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications.
    Triposkiadis F; Karayannis G; Giamouzis G; Skoularigis J; Louridas G; Butler J
    J Am Coll Cardiol; 2009 Nov; 54(19):1747-62. PubMed ID: 19874988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators.
    Vantrimpont P; Rouleau JL; Wun CC; Ciampi A; Klein M; Sussex B; Arnold JM; Moyé L; Pfeffer M
    J Am Coll Cardiol; 1997 Feb; 29(2):229-36. PubMed ID: 9014971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms and implications of autonomic nervous system dysfunction in heart failure.
    Middlekauff HR
    Curr Opin Cardiol; 1997 May; 12(3):265-75. PubMed ID: 9243084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the angiotensin-converting enzyme inhibitor enalapril on sympathetic neuronal function and beta-adrenergic desensitization in heart failure after myocardial infarction in rats.
    Igawa A; Nozawa T; Yoshida N; Fujii N; Kato B; Inoue M; Tazawa S; Yamada Y; Asanoi H; Inoue H
    Jpn Heart J; 2002 Nov; 43(6):675-88. PubMed ID: 12558131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sympathetic activation and the role of beta-blockers in chronic heart failure.
    Krum H
    Aust N Z J Med; 1999 Jun; 29(3):418-27. PubMed ID: 10868514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of renal denervation on cardiac oxidative stress and local activity of the sympathetic nervous system and renin-angiotensin system in acute myocardial infracted dogs.
    Feng Q; Lu C; Wang L; Song L; Li C; Uppada RC
    BMC Cardiovasc Disord; 2017 Feb; 17(1):65. PubMed ID: 28212603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship of the sympathetic nervous system and the renin-angiotensin system in congestive heart failure.
    Francis GS
    Am Heart J; 1989 Sep; 118(3):642-8. PubMed ID: 2570521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Left ventricular dilatation after myocardial infarction: ACE inhibitors, beta-blockers, or both?
    Anthonio RL; van Veldhuisen DJ; van Gilst WH
    J Cardiovasc Pharmacol; 1998; 32 Suppl 1():S1-8. PubMed ID: 9731689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic options of Angiotensin Receptor Neprilysin inhibitors (ARNis) in chronic heart failure with reduced ejection fraction: Beyond RAAS and sympathetic nervous system inhibition.
    Volterrani M; Iellamo F; Senni M; Piepoli MF
    Int J Cardiol; 2017 Jan; 226():132-135. PubMed ID: 27184730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Neuroendocrine activation in heart failure I. Pathophysiology and pharmacological intervention].
    Kjaer A
    Ugeskr Laeger; 2000 Oct; 162(44):5905-9. PubMed ID: 11094549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
    Pfeffer MA
    Am Heart J; 2000 Jan; 139(1 Pt 2):S23-8. PubMed ID: 10618584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neurohormonal assessment in heart failure: from the sophisticated laboratory to practical indications].
    Dei Cas L; Metra M; Visioli O
    G Ital Cardiol; 1993 Feb; 23(2):193-204. PubMed ID: 8098306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes.
    Albaghdadi M; Gheorghiade M; Pitt B
    Eur Heart J; 2011 Nov; 32(21):2626-33. PubMed ID: 21672933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neurohormonal factors in heart failure. II].
    Cosín Aguilar J; Cruz Fernández JM; de Teresa Galván E; Ferreira Montero IJ; López-Sendón J; Soler Soler J; Tamargo Menéndez J
    Rev Esp Cardiol; 1996 May; 49(5):317-27. PubMed ID: 8744385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study.
    Vantrimpont P; Rouleau JL; Ciampi A; Harel F; de Champlain J; Bichet D; Moyé LA; Pfeffer M
    Eur Heart J; 1998 Oct; 19(10):1552-63. PubMed ID: 9820995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of neurohormonal activation in chronic heart failure and postmyocardial infarction.
    Sigurdsson A; Swedberg K
    Am Heart J; 1996 Jul; 132(1 Pt 2 Su):229-34. PubMed ID: 8677861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The neurohumoral axis in congestive heart failure.
    Francis GS; Goldsmith SR; Levine TB; Olivari MT; Cohn JN
    Ann Intern Med; 1984 Sep; 101(3):370-7. PubMed ID: 6147109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.